An Open-Label Study of the Efficacy, Safety, and Tolerability of Oral SCIO-469 in Treatment of Relapsed, Refractory Patients With Multiple Myeloma.
Phase of Trial: Phase II
Latest Information Update: 15 Oct 2010
At a glance
- Drugs Bortezomib; Talmapimod
- Indications Multiple myeloma
- Focus Therapeutic Use
- 15 Oct 2010 Actual end date (Sep 2005) added as reported by ClinicalTrials.gov.
- 15 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Sep 2005 New trial record.